Vivodyne

?? Join Vivodyne – Pioneering the Future of Drug Discovery At Vivodyne, we’re building the next generation of fully human, lab-grown tissues to transform drug discovery—eliminating reliance on animal models and accelerating the path to new treatments. Our interdisciplinary team of scientists, engineers, and AI experts is redefining how medicine is developed. We’re hiring across bioengineering, robotics, hardware design, and AI. If you’re passionate about pushing the boundaries of science and technology to make a real-world impact, we want to hear from you. ?? Explore open roles: www.vivodyne.com/careers #Hiring #DrugDiscovery #Bioengineering #AI #Robotics #BiotechCareers

Our CEO & Co-Founder Andrei Georgescu, Ph.D. spoke at the AI Revolutionizing Therapeutic Drug Development panel at #BiotechShowcase #JPM25. Great session moderated by Maria Luisa Pineda, PhD. at Envisagenics and joined by follow panelists Wyatt McDonnell CEO of Infinimmune, Kfir Schreiber CEO, DeepCure, Hannah Wastyk CEO Interface Biosciences and Khai Minh Pham MD, PhD (AI) CEO ThinkingNode Life Science, Inc. Looking forward to sharing more news updates this year! ????

Meet with the Vivodyne team at #JPM25! ???? Our CEO Andrei Georgescu, Ph.D. and Chief Operating Officer Julie O'Shaughnessy will be on-site Jan 13-15 at the conference. Andrei will also be speaking on the following panel at Biotech Showcase: AI, ML, & LLM: Revolutionizing Therapeutic Development ?? Biotech Showcase ?? San Francisco, CA ?? January 15, 2025 ?? 14:30 – 15:30 Large language models (LLMs) and artificial intelligence (AI) are transforming the pharmaceutical industry by streamlining processes across the entire drug development lifecycle. These technologies enable researchers to generate hypotheses, extract insights from vast datasets, detect patterns, and simplify literature searches through natural language interactions. Beyond drug discovery, AI has the potential to revolutionize various aspects of therapeutic development, including research, clinical trials, regulatory filings, and manufacturing. Inquiries can be directed to: [email protected]. Looking forward to seeing everyone there!

AI, ML, & LLM: Revolutionizing Therapeutic Development ?? Biotech Showcase ?? San Francisco, CA ?? January 15, 2025 ?? 14:30 – 15:30 Large language models (LLMs) and artificial intelligence (AI) are transforming the pharmaceutical industry by streamlining processes across the entire drug development lifecycle. These technologies enable researchers to generate hypotheses, extract insights from vast datasets, detect patterns, and simplify literature searches through natural language interactions. Beyond drug discovery, AI has the potential to revolutionize various aspects of therapeutic development, including research, clinical trials, regulatory filings, and manufacturing. This session is open to life science professionals. Take advantage of this opportunity to explore the program and experience what Biotech Showcase has to offer. RSVP is required to reserve your spot! RSVP now >>?https://lnkd.in/gHhFJN5S Moderator: Maria Luisa Pineda, PhD. ? Panelists: Andrei Georgescu, Ph.D. Wyatt McDonnell Khai Minh Pham MD, PhD (AI) Kfir Schreiber Hannah Wastyk ? #BiotechShowcase #SanFrancisco Sara Jane Demy

We are building the Hubble.

2024 Forbes Healthcare Summit | The New Era Of Drug Discovery ???? The past decade has seen amazing new technologies for drugs, but the process of drug discovery itself is still a costly process that can take the better part of a decade. But AI promises to change all that. Forbes Science & Health Senior Editor Alex Knapp sits down with Vivodyne Cofounder & CEO Andrei Georgescu, Ph.D., Basecamp Research Cofounder & CEO Glen Gowers, Ph.D., and Verge Genomics Cofounder & CEO Alice Zhang, entrepreneurs on the cutting edge of drug discovery to see how #AI, data and advances in the #lab are all contributing to developing new medications faster. ???? Watch the panel discussion: ???? https://lnkd.in/e8g8ykW2

As we close out 2024, this must-watch panel discussion from Pre-JPM Partnering Week dives deep into a transformative year for the #lifesciences industry. Experts break down major deals, regulatory milestones, funding trends, and M&A activity, while offering real-world examples of successful collaborations and emerging sector trends. Looking ahead to 2025, the panel also explores the challenges and opportunities that will shape the industry’s future. Whether you're reflecting on the past year or planning your next move, this session is packed with insights to help you stay ahead. ?? Watch the full session now on YouTube: https://lnkd.in/ggDeF4xp Moderator: - Kimberly Ha, Founder & CEO, KKH Advisors Panelists: - Wyatt McDonnell, Co-Founder & CEO, Infinimmune - Julie O'Shaughnessy, Chief Operating Officer, Vivodyne - Willie T. Reaves Jr., Head of Public Engagement, Cellino #biotech #PreJPMWeek #healthcare #JPM25 #BTGDigitalPartnering #BioWeekSF #JPMWeek #MedTech #DigitalHealth #BiotechBuddies #JPM2025

We’re excited to announce our recent paper with GSK, "Self-organization of the hematopoietic vascular niche and emergent innate immunity on a chip," published in the journal, Cell Stem Cell. Using Vivodyne's technology, researchers were able to develop an innovative bioengineering approach to recreate human bone marrow outside the body. Using a method inspired by natural development, we combined human blood-forming stem cells with blood vessel cells in a 3D system. This setup allows the cells to self-organize into lifelike, vascularized tissue resembling the bone marrow environment. We used this system to model how bone marrow is damaged by radiation and how the immune system reacts to a bacterial lung infection. We’ve also built an advanced platform that automates these processes, enabling large-scale testing of cancer drugs for potential harmful effects on bone marrow. Our technology opens exciting new possibilities for studying human biology on real human tissues to improve drug development. Read the paper: https://lnkd.in/gydE3G5M

"We want to be able to do in human tissue what we do in mice, which is we reiterate and refine." Andrei Georgescu, Ph.D., Vivodyne cofounder and CEO, spoke about drug discovery at the 2024 Forbes Healthcare Summit. #ForbesHealth https://lnkd.in/ekZiQXJf

Our CEO & Co-Founder Andrei Georgescu, Ph.D. will be speaking at the Forbes Healthcare Summit in New York this Wednesday Dec 4, 3:55-4:20 pm ET. ???? The New Era Of Drug Discovery The past decade has seen amazing new technologies for drugs, but the process of drug discovery itself is still a costly process that can take the better part of a decade. But AI promises to change all that. Join this panel of entrepreneurs on the cutting edge of drug discovery to see how AI, data and advances in the lab are all contributing to developing new medications faster. The panel will be moderated by senior editor Alex Knapp. Andrei will be joined by Alice Zhang CEO at Verge Genomics and Glen Gowers Co-Founder at Basecamp Research. Sharing more info here: ???? https://lnkd.in/evg3sgSf